Disease activity indexes might not capture the same disease aspects in males and females with ankylosing spondylitis: A real-world nationwide analysis.

Autor:	Fernández-Carballido C; Department of Rheumatology, Hospital Universitario San Juan de Alicante, Alicante, Spain., Jovaní V; Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante Institute of Health and Biomedical Research (ISABIAL), Alicante, Spain., Catalán EB; Department of Rheumatology, Hospital del Mar, Barcelona, Spain., Moreno-Ramos MJ; Department of Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain., Sanz Sanz J; Department of Rheumatology, Hospital Universitario Puerta de Hierro, Madrid, Spain., Gallego A; Department of Rheumatology, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain., García Vivar ML; Department of Rheumatology, Hospital Universitario Basurto, Bilbao, Spain., Rodríguez-Heredia JM; Department of Rheumatology, Hospital Universitario de Getafe, Madrid, Spain., Sanabra C; Novartis Farmacéutica, Barcelona, Spain., Sastré C; Novartis Farmacéutica, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in medicine [Front Med (Lausanne)] 2022 Dec 21; Vol. 9, pp. 1078325. Date of Electronic Publication: 2022 Dec 21 (Print Publication: 2022).
DOI:	10.3389/fmed.2022.1078325
Abstrakt:	Background: To evaluate gender differences in disease activity and health status (HS) in patients with radiographic axial spondyloarthritis (r-axSpA)/ankylosing spondylitis (AS). Methods: Ancillary analysis of the MIDAS study, an observational, non-interventional, cross-sectional and retrospective multicenter nationwide study to assess disease activity and its relationship with HS in clinical practice. Adult patients with AS diagnosis, fulfilling ASAS and modified New York criteria, treated for ≥3 months upon study inclusion according to clinical practice were included. The primary outcome was "disease control" assessed by the percentage of patients in remission and low disease activity (BASDAI and ASDAS-CRP scores). HS was evaluated using the ASAS health index (ASAS-HI). Patients' responses and characteristics were analyzed by gender. Results: We analyzed 313 patients with AS, 237 (75.7%) males and 76 (24.3%) females. A total of 202 (64.5%) patients had adequate disease control (BASDAI < 4); 69.2% of males [mean (SD) BASDAI 2.9 (2.1)] and 50.0% of females [mean (SD) BASDAI 3.8 (2.4); p = 0.01]. According to ASDAS-CRP, 57.5% of patients were adequately controlled (ASDAS-ID +ASDAS-LDA); 138 (58.2%) males and 42 (55.3%) females. The mean (SD) ASDAS-CRP was 1.9 (1.1); being 1.9 (1.0) in males and 2.0 (1.1) in females. Overall, the impact of AS on HS was low to moderate [mean (SD) ASAS-HI 5.8 (4.4)]; being 5.5 (4.4) for males and 6.8 (4.2) for females ( p = 0.02). Conclusion: This study showed a higher proportion of females with AS and active disease using the BASDAI definition. When using the ASDAS-CRP definition these differences by gender were less pronounced. The impact of disease activity on HS appears to be higher in females than males. Competing Interests: CF-C has received consulting fees from AbbVie, Novartis, Janssen, UCB, and Lilly and received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AbbVie, Novartis, Janssen, Pfizer, MSD, UCB, and Lilly, and support for attending meetings and/or travel from AbbVie, Novartis, Janssen, Roche, UCB, and Lilly. In addition, CF-C participated on Advisory Boards of AbbVie, Novartis, Janssen, UCB, and Lilly. EBC has received consulting fees from AbbVie, Novartis, Janssen, UCB, and Lilly and received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AbbVie, Novartis, Janssen, Pfizer, MSD, UCB, and Lilly, and support for attending meetings and/or travel from AbbVie, Novartis, Janssen, Roche, UCB, and Lilly. JS has received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AbbVie, Novartis, Janssen, Pfizer, UCB, and Amgen, and support for attending meetings and/or travel from Novartis and Janssen. MG has received grants or contracts from Amgen and AbbVie. She received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from AbbVie, Bristol, Novartis, Janssen, Pfizer, Amgen, and Lilly, and support for attending meetings and/or travel from Janssen, Lilly, and UCB. JR-H has received payment or honoraria for lectures, presentations, speakers' bureaus, manuscript writing or educational events from Novartis, Janssen, and Biogen. CSan and CSas are Novartis employees. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Fernández-Carballido, Jovaní, Catalán, Moreno-Ramos, Sanz Sanz, Gallego, García Vivar, Rodríguez-Heredia, Sanabra and Sastré.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu